+224.1%
GDX vs MRNA
-67.9%
+292.0%
-46.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | +5.4% | -4.3% | +0.7% |
| 7D | -2.2% | -1.1% | -1.1% | -2.1% |
| 30D | +6.8% | +126.1% | -119.4% | -4.8% |
| 3M | +24.9% | +190.0% | -165.1% | +8.4% |
| 6M | -4.2% | +157.2% | -161.4% | -16.1% |
| YTD | +13.2% | +388.2% | -375.0% | -5.9% |
| 1Y | +40.2% | +467.0% | -426.8% | +15.0% |
| 3Y | +249.6% | +36.1% | +213.5% | +207.5% |
| All | +224.1% | -67.9% | +292.0% | +189.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling